or
forgot password

Autologous Bone Marrow Transplantation for Acute Non-Lymphoblastic Leukemia During First or Subsequent Remission


Phase 2
16 Years
69 Years
Not Enrolling
Both
Leukemia, Myelocytic, Acute, Leukemia, Blood and Marrow Transplant (BMT)

Thank you

Trial Information

Autologous Bone Marrow Transplantation for Acute Non-Lymphoblastic Leukemia During First or Subsequent Remission


To use high dose chemotherapy with autologous stem cell rescue to try to increase the chance
of long term control and cure of the disease.


Inclusion Criteria:

- must be in remission

- adequate organ function

Exclusion Criteria:- prior MDS

- active infection

- liver disease

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Disease free survival (DFS)

Outcome Time Frame:

unknown

Safety Issue:

No

Principal Investigator

Laura Johnston

Investigator Role:

Principal Investigator

Investigator Affiliation:

Stanford University

Authority:

United States: Institutional Review Board

Study ID:

BMT8N

NCT ID:

NCT00186381

Start Date:

November 1995

Completion Date:

March 2007

Related Keywords:

  • Leukemia, Myelocytic, Acute
  • Leukemia
  • Blood and Marrow Transplant (BMT)
  • Leukemia
  • Leukemia, Myeloid, Acute
  • Leukemia, Myeloid

Name

Location
Stanford University School of Medicine Stanford, California  94305-5317